Evidence map›Paper›PMID 26499110›Full record

ArticleBMC biotechnology2015

Transcriptome study and identification of potential marker genes related to the stable expression of recombinant proteins in CHO clones.

Uros Jamnikar, Petra Nikolic, Ales Belic, Marjanca Blas, Dominik Gaser, Andrej Francky, Holger Laux, Andrej Blejec, Spela Baebler, Kristina Gruden

Open access · goldAbstract read
In one paragraph

Article in BMC biotechnology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Uros JamnikarSandoz Biopharmaceuticals, Kolodvorska 27, SI-1234, Menges, Slovenia. uros.jamnikar@sandoz.com.
Petra NikolicJozef Stefan Institute, Jamova cesta 39, SI-1000, Ljubljana, Slovenia. petra.nikolic@ijs.si.
Ales BelicSandoz Biopharmaceuticals, Kolodvorska 27, SI-1234, Menges, Slovenia. ales.belic@sandoz.com.
Marjanca BlasSandoz Biopharmaceuticals, Kolodvorska 27, SI-1234, Menges, Slovenia. marjanca.blas@sandoz.com.
Dominik GaserSandoz Biopharmaceuticals, Kolodvorska 27, SI-1234, Menges, Slovenia. dominik.gaser@sandoz.com.
Andrej FranckySandoz Biopharmaceuticals, Kolodvorska 27, SI-1234, Menges, Slovenia. andrej.francky@sandoz.com.
Holger LauxNovartis Pharma AG, WKL-681.1.08, 4002, Basel, Switzerland. holger.laux@novartis.com.
Andrej BlejecNational Institute of Biology, Vecna pot 111, SI-1000, Ljubljana, Slovenia. andrej.blejec@nib.si.
Spela BaeblerNational Institute of Biology, Vecna pot 111, SI-1000, Ljubljana, Slovenia. spela.baebler@nib.si.
Kristina GrudenNational Institute of Biology, Vecna pot 111, SI-1000, Ljubljana, Slovenia. kristina.gruden@nib.si.
Sanden (Japan) · JPNational Institute of Biology · SIJožef Stefan Institute · SINovartis (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChinese hamster ovary (CHO) cells have become the host of choice for the production of recombinant proteins, due to their capacity for correct protein folding, assembly, and posttranslational modifications. The most widely used system for recombinant proteins is the gene amplification procedure that uses the CHO-Dhfr expression system. However, CHO cells are known to have a very unstable karyotype. This is due to chromosome rearrangements that can arise from translocations and homologous recombination, especially when cells with the CHO-Dhfr expression system are treated with methotrexate hydrate. The present method used in the industry for testing clones for their long-term stability of recombinant protein production is empirical, and it involves their cultivation over extended periods of time prior to the selection of the most suitable clone for further bioprocess development. The aim of the present study was the identification of marker genes that can predict stable expression of recombinant genes in particular clones early in the development stage.

resultsThe transcriptome profiles of CHO clones with stable and unstable recombinant protein production were investigated over 10-weeks of cultivation, using a DNA microarray. We identified 14 genes that were differentially expressed between the stable and unstable clones already at 2 weeks from the beginning of the cultivation. Their expression was validated by reverse-transcription quantitative real-time PCR (RT-qPCR). Furthermore, the k-nearest neighbour algorithm approach shows that the combination of the gene expression patterns of only five of these 14 genes is sufficient to predict stable recombinant protein production in clones in the early phases of cell-line development.

conclusionsThe exact molecular mechanisms that cause unstable recombinant protein production are not fully understood. However, the expression profiles of some genes in clones with stable and unstable recombinant protein production allow prediction of such instability early in the cell-line development stage. We have thus developed a proof-of-concept for a novel approach to eliminate unstable clones in the CHO-Dhfr expression system, which saves time and labour-intensive work in cell-line development.

Indexed as

AnimalsCHO CellsCricetinaeCricetulusGene Expression ProfilingGenetic MarkersOligonucleotide Array Sequence AnalysisReal-Time Polymerase Chain ReactionRecombinant ProteinsTranscriptomeGenetic MarkersRecombinant Proteins

Identifiers

PMID26499110
PMCPMC4812793
OpenAlexW1837971797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.